Author Contributions: Drs Jiang and Boyle had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Jiang, Kuchibhatla, Kuhn, O’Connor.
Acquisition of data: Jiang, Velazquez, Kuchibhatla, Samad, Kuhn, Ortel, Rogers, O’Connor.
Analysis and interpretation of data: Jiang, Velazquez, Kuchibhatla, Samad, Boyle, Kuhn, Becker, Ortel, Williams, Rogers, O’Connor.
Drafting of the manuscript: Jiang, Velazquez, Boyle.
Critical revision of the manuscript for important intellectual content: Jiang, Velazquez, Kuchibhatla, Samad, Kuhn, Becker, Ortel, Williams, Rogers, O’Connor.
Statistical analysis: Kuchibhatla, Boyle.
Obtained funding: Jiang, Kuchibhatla.
Administrative, technical, or material support: Jiang, Velazquez, Kuhn, Ortel, O’Connor.
Study supervision: Jiang, Velazquez, Samad, Kuhn, Rogers, O’Connor.
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. All authors reported receiving salary support through a National Heart, Lung, and Blood Institute (NHLBI) research grant. Dr Jiang reported that she is named on a patent application to Duke University related to selective serotonin reuptake inhibitor (SSRI) treatment for mental stress–induced myocardial ischemia (MSIMI). Dr Velazquez reported receiving research grants from Abbott Laboratories, Evalve, and Ikaria; receiving consulting fees from Boehringer Ingelheim, Gilead, and Novartis; and that he is named on a patent application to Duke University related to SSRI treatment for MSIMI. Dr Samad reported receiving a grant or grant pending from the American Society of Echocardiography. Dr Becker reported receiving research grant support from Baxter, Bristol-Myers Squibb, Johnson & Johnson, and Regado Biosciences; receiving consulting/lecture fees from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Johnson & Johnson, Merck, Regado Biosciences, and sanofi-aventis. Dr Ortel reported serving as a consultant for Instrumentation Laboratory, Boehringer Ingelheim, and Bayer and receiving grants or grants pending from GlaxoSmithKline, Eisai, Pfizer, Daiichi Sankyo, Instrumentation Laboratory, and Stago. Dr Williams reported holding a US patent on the 5HTTLPR L allele for use as a marker of increased cardiovascular risk in stressed persons and that he is a founder and major stockholder of Williams LifeSkills Inc. Dr Rogers reported receiving funding from Boston Scientific Corporation, HeartWare, and Thoratec Corporation. Dr O’Connor reported receiving funding from Actelion Pharmaceuticals Ltd, Amgen Inc, Biscardia LLC, Faculty Connection, GE Healthcare, Ikaria, Novella Clinical Inc, Pfizer Inc, Pozen, and Roche Diagnostics; serving as a consultant for Novartis, Heartware, ResMed, Johnson & Johnson, Gilead, Critical Diagnostics, BG Medicine, Otsuka, Astellas, Cytokinetics, and Capricor; holding stock or stock options in Neurotronik/Interventional Autonomics Corporation; that he is named on a patent application to Duke University related to SSRI treatment for MSIMI; and serving as a journal editor for the American College of Cardiology. No other authors reported disclosures.
Funding/Support: The REMIT study was funded by the NHLBI (R01 HL085704), Bethesda, Maryland. Escitalopram and matched placebo were supplied by Forest Research Institute Inc, Germantown, Maryland.
Role of the Sponsor: The sponsors of this study had no role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; or the preparation, review, or approval of the manuscript.
Online-Only Material: Author Video Interview is available here.
Additional Contributions: We would like to thank Kirkwood Adams, MD (Department of Medicine, University of North Carolina–Chapel Hill School of Medicine), Alan Miller, MD (Department of Medicine, University of Florida College of Medicine–Jacksonville), and Zhen Huang, MS (Duke Clinical Research Institute–Statistics, Durham, North Carolina), for their contributions as the data and safety monitoring board of the REMIT study. These persons received no compensation from REMIT trial funding sources for their contributions. We would like also to thank Jonathan McCall, MS, for his editorial assistance. Mr McCall, an employee of the Duke Clinical Research Institute, received no compensation for his work on this manuscript other than his usual salary.
This article was corrected for errors on May 21, 2013.